huma-signs-partnership-with-merck-kgaa,-darmstadt,-germany-to-support-cancer-care

Huma signs partnership with Merck KGaA, Darmstadt, Germany to support cancer care

 

Huma Therapeutics (“Huma”), a leading global digital health company, and Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a partnership to develop a digital solution that aims to help cancer patients better understand and manage their conditions and treatment. The Cross-Indication Disease Management Platform will be made available to patients being treated with Merck KGaA, Darmstadt, Germany’s cancer therapies.

Set for initial launch in 2024, the preliminary direct-to-patient solution will support urothelial carcinoma patients in the UK.

Regulated platform will drive improved treatment adherence

Utilising Huma’s disease-agnostic Software as a Medical Device (SaMD) technology platform, the first of its kind to achieve both EU MDR Class IIb regulation and FDA Class 2 510(k) clearance, the collaboration between Huma and Merck KGaA, Darmstadt, Germany aspires to (with local specifications):

  • Increase patient understanding of their condition and treatment protocols, encouraging adherence to prescribed treatment
  • Encourage discussions between patients and their care team
  • Deliver timely educational content
  • Support connections between patients and caregivers, fostering a supportive community network

Dan Vahdat, CEO and Founder of Huma, said: “Huma is dedicated to advancing the frontier of digital-first care and research. Our collaboration with Merck KGaA, Darmstadt, Germany is a pivotal step towards amplifying our impact on patient care both at the individual and systemic level. Our recent regulatory achievements mark a significant milestone, streamlining our ability to introduce innovative digital companion applications, alongside more sophisticated AI algorithms that may support patients and healthcare professionals alike. We are thrilled to join forces with Merck KGaA, Darmstadt, Germany, to develop this ambitious oncology platform.”

Dr Mert Aral, Chief Medical Officer, Huma, said: “A number of well-designed scientific studies have underscored the pivotal role digital health technologies can play in optimising care pathways in oncology, improving patient outcomes. In this significant collaboration with Merck KGaA, Darmstadt, Germany, the project strives to simplify the complex journey that cancer patients often face. The goal is straightforward – to deepen the understanding of patients about their condition, help them to navigate intricate care pathways seamlessly and to facilitate sustained adherence to therapies.”

emd-electronics-announces-$1-billion-investment-in-us-to-support-semiconductor-customers

EMD Electronics Announces $1 Billion Investment in US to Support Semiconductor Customers

 

EMD Electronics, the North American Electronics business of Merck KGaA, Darmstadt, Germany, today announced approximately $1 billion in investments through 2025 in the US to accelerate growth opportunities in the electronics market. EMD Electronics will heavily invest in R&D and capacity. Over the next five years, the company plans to spend around $2.5 billion globally in long-term fixed assets (CapEx) in Semiconductor and Display Solutions.

“The chip shortage needs industry-wide cooperation to resolve the supply chain issues consumers are currently facing. We are investing in the US to expand our production capacity and innovation footprint to support our customers’ ambitious growth plans,” said Kai Beckmann, Member of the Executive Board of Merck KGaA, Darmstadt, Germany, and CEO Electronics.

In the US, EMD Electronics plans to invest primarily in its ArizonaCaliforniaTexas, and Pennsylvania sites. As part of the “Level Up” growth program which includes a global investment of significantly more than $3.5 billion, the company seeks to capture the growth opportunities that come along with the significantly accelerating global demand for innovative semiconductor and display materials. This demand is driven by exponential data growth and highly impactful technology trends such as Artificial Intelligence (AI), the Internet of Things and 5G. The global investment also adds to the ambition of Merck KGaA, Darmstadt, Germany, to accelerate growth by investing in its “Big 3” businesses, including the Semiconductor Solutions business unit as a key driver.

The Level Up growth program focuses on four mutually reinforcing key priorities: Scale, Technology, Portfolio, and Capabilities. Further investing in these four areas builds the foundation of the company’s more ambitious growth targets, in conjunction with the strong demand for electronics materials, particularly semiconductors. The priorities Scale and Technology support the massive capacity expansion that is happening globally in the semiconductor and electronics industries fueled by large-scale investments from its customers. Under the priority area Portfolio, the company seeks to exploit attractive, external growth opportunities via selected bolt-on acquisitions. Furthermore, Level Up will initiate or accelerate important internal initiatives under the Capabilities priority.

All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.